-
平臺(tái)編號(hào)：bio-69185
-
國(guó)際編號(hào)：HTB-175?
-
細(xì)胞信息： NCI-H82
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
NCI-H82
是否是腫瘤細(xì)胞：1
物種來(lái)源：人
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
年限：40 years
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：HTB-175?
相關(guān)疾?。盒〖?xì)胞肺癌
器官來(lái)源：肺
細(xì)胞形態(tài)：上皮樣
數(shù)量：大量
規(guī)格：0.1ml Designations: NCI-H82 [H82]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP)
Tumorigenic:Yes
Oncogene:myc +; myb -; raf +; ras +; fms +; fes +
DNA Profile (STR):Amelogenin: X
CSF1PO: 11
D13S317: 8
D16S539: 12
D5S818: 12
D7S820: 10,13
THO1: 9,9.3
TPOX: 11
vWA: 14
Cytogenetic Analysis:This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations.
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1
Me-2, 1
PGM1, 1-2
PGM3, 1-2
Age: 40 years
Gender: male
Ethnicity: Caucasian
Comments:The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung.
The morphology of the original tumor was not characteristic of SCLC.
The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase.
It does not have detectable levels of L-DOPA decarboxylase or bombesin.
The cells produce an abnormally sized p53 mRNA (3.7 kb).
C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells.
The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern.
The cells stain positively for neurofilaments and vimentin.
There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended
Medium Renewal: 2 to 3 times per week
This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201
1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141
23042: Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258
23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370
23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389
32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760
32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
物種來(lái)源：人
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
年限：40 years
運(yùn)輸方式：凍存運(yùn)輸
ATCC Number：HTB-175?
相關(guān)疾?。盒〖?xì)胞肺癌
器官來(lái)源：肺
細(xì)胞形態(tài)：上皮樣
數(shù)量：大量
規(guī)格：0.1ml Designations: NCI-H82 [H82]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP)
Tumorigenic:Yes
Oncogene:myc +; myb -; raf +; ras +; fms +; fes +
DNA Profile (STR):Amelogenin: X
CSF1PO: 11
D13S317: 8
D16S539: 12
D5S818: 12
D7S820: 10,13
THO1: 9,9.3
TPOX: 11
vWA: 14
Cytogenetic Analysis:This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations.
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1
Me-2, 1
PGM1, 1-2
PGM3, 1-2
Age: 40 years
Gender: male
Ethnicity: Caucasian
Comments:The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung.
The morphology of the original tumor was not characteristic of SCLC.
The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase.
It does not have detectable levels of L-DOPA decarboxylase or bombesin.
The cells produce an abnormally sized p53 mRNA (3.7 kb).
C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells.
The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern.
The cells stain positively for neurofilaments and vimentin.
There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended
Medium Renewal: 2 to 3 times per week
This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201
1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
22446: Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141
23042: Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258
23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370
23104: Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389
32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760
32287: Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
